Loading news...
Heartflow's (NASDAQ: HTFL - Get Free Report) lock-up period is set to end on Wednesday, February 4th. Heartflow had issued 16,666,667 shares in its public offering on August 8th. The total size of the offering was $316,666,673 based on an initial share price of $19.00. After the end of Heartflow's lock-up period, restrictions preventing major shareholders
Baillie Gifford and Co. bought a new position in Heartflow, Inc. (NASDAQ: HTFL) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 3,005,998 shares of the company's stock, valued at approximately $101,182,000. Baillie Gifford and Co. owned 3.60% of Heartflow as of its most recent filing
HeartFlow, Inc. (HTFL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis is now covered by Aetna across all lines of business, including Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans.
MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
Jeffrey Lightcap, a member of the Board of Directors of HeartFlow (HTFL 2.00%), acquired 40,000 common shares in an open-market transaction valued at $1,053,680 on Dec. 16, 2025; see SEC Form 4 filing.
The specialized healthcare diagnostics company earned two endorsements from heart health organizations. These concerned HeartFlow's plaque detection product.
Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment
Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health Service Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health Service
Tulsa-based Schusterman Interests added 1,939,201 shares of HeartFlow valued at $65.3 million in the third quarter. The position represents 14.9% of the fund's 13F reportable assets under management.
Added 12,448,158 shares in a new position, increasing reported holdings by $419.00 million Post-trade, the fund holds 12,448,158 shares worth $419.00 million The position now represents 27.81% of fund AUM, making it the fund's 1st-largest holding
MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference.
Acquired 312,234 shares of HeartFlow, estimated at ~$10.51 million based on quarterly average price Post-trade position: 312,234 shares, valued at $10.51 million as of 2025-09-30 New position places HeartFlow outside the fund's top five holdings by reported value
MOUNTAIN VIEW, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today reported financial results for the three months ended September 30, 2025.
The market has recently absorbed a surge of activity around AI infrastructure buildouts. NVIDIA CEO Jensen Huang proclaimed in September that global AI infrastructure spending could total $3 trillion to $5 trillion by 2030. As we have written before, technology spending today accounts for just 5% of global GDP.
NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association (AHA) Scientific Sessions 2025. The new data add to the robust and growing body of evidence supporting AI-powered Heartflow Plaque Analysis with Heartflow Plaque Staging* — the most clinically validated framework for actionable CAD care.
MOUNTAIN VIEW, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic value of Heartflow Plaque Analysis at the American Heart Association (AHA) Scientific Sessions 2025, taking place November 7-10 in New Orleans.
MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025.
PLAN CALCIUM study to be presented at TCT 2025 conference highlights how AI-powered plaque analysis can inform lesion preparation and calcium modification planning NAVIGATE-PCI registry to enroll approximately 2,500 patients across approximately 30 sites to evaluate the impact of CT-guided PCI planning in real-world practice MOUNTAIN VIEW, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today introduced Heartflow PCI Navigator, the newest addition to the Heartflow One platform.
Heartflow secures FDA clearance and Cigna coverage for its Next Gen Plaque Analysis, boosting accuracy and nationwide access.